Tranexamic Acid Trial Signals Overdue Shift to Routine Perioperative Use Across Non-Cardiac Surgeries, Exposing Gaps in Blood Conservation Policy

The NEJM-published cluster-crossover RCT (n=8,273 major surgeries at 10 Canadian hospitals, Feb 2022–Mar 2024) demonstrated tranexamic acid cut transfusion rates from 9.8% to 7.4% with no increase in 90-day venous thromboembolism (both arms 2.1%), a finding robust given the pragmatic design that leveraged administrative data from ICES and Manitoba. Unlike smaller prior cardiac and orthopedic trials, this study deliberately enrolled ~5,000 cancer patients—a group routinely excluded—revealing safety in oncologic procedures where bleeding risk intersects with hypercoagulability. Mainstream coverage underplays the cluster-crossover efficiency that enabled rapid, low-cost evidence generation versus traditional RCTs, and overlooks how a <$10 drug versus >$700 per transfusion unit could avert 50,000 Canadian blood units yearly while addressing supply shortages documented in observational transfusion registries. Related evidence from the earlier POISE-3 trial on perioperative bleeding reinforces the pattern of antifibrinolytic benefit without thrombotic harm, yet policy inertia persists. Conflicts of interest appear minimal as university- and hospital-led investigators reported no pharma funding; study quality as large pragmatic RCT exceeds typical observational perioperative data. Adoption could standardize care across head, chest, abdomen, and pelvis procedures, a scale missed by outlets fixated on novel biologics.